title: Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.
abstract: Cardiovascular disease is the leading cause of death among adults in the USA. Both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) are known risk factors for cardiovascular disease. Despite the development of numerous effective anti-glycemic therapies, we have been unable to completely mitigate cardiovascular risk with glucose lowering alone, and prevention of cardiovascular disease in patients with diabetes is primarily achieved with the use of medications that address other risk factors such as anti-hypertensives or statins. Glucagon-like peptide-1 (GLP-1) is a key hormone in the pathophysiology of diabetes. GLP-1 agonists have been recently approved for the treatment of T2DM as well as for chronic weight management. In this review, we aim to explore the effects of GLP-1 agonists on cardiovascular health with a focus on cardiometabolic variables and cardiac function.
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
authors.forename: Ashish
authors.initials: A
authors.lastname: Sarraju
authors.affiliation: Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
authors.forename: Sun H
authors.initials: SH
authors.lastname: Kim
authors.affiliation: Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University School of Medicine, Falk CVRC, Room CV273, MC 5406, 300 Pasteur Drive, Stanford, CA, 94305, USA. knowlej@stanford.edu.
authors.forename: Joshua W
authors.initials: JW
authors.lastname: Knowles
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control* / Q000601:surgery; D004727:Endothelium / Q000187:drug effects; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D052216:Glucagon-Like Peptide 1
keywords: ASCVD risk factors; Atherosclerosis; Cardiovascular disease; Diabetes; GLP-1 agonists; Glucagon-like peptide-1; Heart failure; Mortality